CXCR4 and glioblastoma: Rubin et al., used intracranial xenograft models of GBM and medulloblastoma to illustrate that the systemic administration of AMD3100 (CXCR4 antagonist) reduced proliferation and increased apoptosis in tumor cells within 48 h [40].